ChiCTR2300070571 版本V1.1 版本创建时间2023/06/01 20:10:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300070571 

最近更新日期:

Date of Last Refreshed on:

2023-04-17 14:30:06 

注册时间:

Date of Registration:

2023-04-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

症状性颅内动脉粥样硬化卒中复发预测模型的探索研究

Public title:

An exploratory Study of Predictive Model of Stroke Recurrence in Patients With Symptomatic Intracranial Atherosclerotic Disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

症状性颅内动脉粥样硬化卒中复发预测模型的探索研究

Scientific title:

An exploratory Study of Predictive Model of Stroke Recurrence in Patients With Symptomatic Intracranial Atherosclerotic Disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

宋小燕 

研究负责人:

宋小燕 

Applicant:

Xiaoyan Song 

Study leader:

Xiaoyan Song 

申请注册联系人电话:

Applicant telephone:

+86 21 37798584

研究负责人电话:

Study leader's telephone:

+86 21 37798584

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cxcsxy@sina.com

研究负责人电子邮件:

Study leader's E-mail:

cxcsxy@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市虹口区海宁路100号上海市第一人民医院神经内科

研究负责人通讯地址:

上海市虹口区海宁路100号上海市第一人民医院神经内科

Applicant address:

Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study leader's address:

Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

申请注册联系人邮政编码:

Applicant postcode:

200080

研究负责人邮政编码:

Study leader's postcode:

200080

申请人所在单位:

上海市第一人民医院

Applicant's institution:

Shanghai General Hospital

研究负责人所在单位:

上海市第一人民医院

Affiliation of the Leader:

Shanghai General Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

院伦快【2023】144 号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第一人民医院人体试验伦理审查委员会

Name of the ethic committee:

Ethics Review Committee for Human Research of Shanghai General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-04-11 00:00:00

伦理委员会联系人:

耿雯倩

Contact Name of the ethic committee:

Wenqian Geng

伦理委员会联系地址:

上海市虹口区海宁路100号上海市第一人民医院临床研究中心

Contact Address of the ethic committee:

Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 36123569

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第一人民医院

Primary sponsor:

Shanghai General Hospital

研究实施负责(组长)单位地址:

上海市虹口区海宁路100号

Primary sponsor's address:

Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第一人民医院

具体地址:

上海市虹口区海宁路100号

Institution
hospital:

Shanghai General Hospital

Address:

Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

经费或物资来源:

上海市第一人民医院院级特色项目

Source(s) of funding:

Shanghai General Hospital

Target disease:

Stroke

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

验证RRE90在预测症状性颅内动脉粥样硬化卒中复发中的价值,探讨新的预测因子。  

Objectives of Study:

To verify the value of RRE90 in predicting the stroke recurrence of symptomatic intracranial atherosclerotic Disease(ICAD) and explore new predictive factors.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①年龄≥18岁的缺血性卒中患者,发病2周内入院;②经过详细的检查,考虑病因为症状ICAD所致.

Inclusion criteria

① Patients with acute ischemic stroke caused by the symptomatic ICAD,aged ≥ 18 years.

排除标准:

①任何潜在的心源性栓子(包括慢性或阵发性房颤,二尖瓣狭窄,机械瓣膜,心内膜炎,心内血栓或赘生物,3个月内心肌梗死,扩张性心肌病,射血分数低于30%);②小血管病所致梗死;③颅外动脉粥样硬化所致梗死(同侧颅外血管存在≥50%狭窄);④其他病因所致梗死;⑤曾行或者拟行颅内动脉狭窄介入手术治疗;⑥已知的颅内肿瘤,动静脉畸形或动脉瘤;⑦禁忌行MRI检查;⑧任何严重或威胁生命的合并症致预期寿命少于3个月。

Exclusion criteria:

① Any potential cardiac embolus; ② Infarction caused by small vessel disease; ③ Infarction caused by extracranial atherosclerosis (≥ 50% stenosis of ipsilateral extracranial vessels); ④ Infarction caused by other causes; ⑤ Interventional surgery for intracranial artery stenosis has been performed or is planned to be performed; ⑥ Known intracranial tumor, arteriovenous malformation or aneurysm; ⑦ MRI examination is contraindicated; ⑧ Life expectancy is less than 3 months due to any serious or life-threatening complication.

研究实施时间:

Study execute time:

From 2023-05-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-05-01 00:00:00 To 2024-12-31 00:00:00  

干预措施:

Interventions:

组别:

1

样本量:

400

Group:

1

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

上海 

Country:

China 

Province:

Shanghai 

City:

Shanghai 

单位(医院):

上海市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

卒中复发

指标类型:

主要指标

Outcome:

Stroke Recurrence

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心血管和脑血管事件

指标类型:

次要指标

Outcome:

Cardiovascular and cerebrovascular events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

死亡事件

指标类型:

次要指标

Outcome:

Mortality events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

观察性研究,非随机化

Randomization Procedure (please state who generates the random number sequence and by what method):

Observational study, non-randomized

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-04-17 14:29:34